Share on StockTwits

Research analysts at ING started coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report released on Monday. The firm set a “buy” rating and a $11.00 price target on the stock. ING’s target price points to a potential upside of 36.99% from the company’s current price.

Separately, analysts at TheStreet downgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $10.26.

Shares of LeMaitre Vascular (NASDAQ:LMAT) opened at 8.03 on Monday. LeMaitre Vascular has a 52 week low of $6.02 and a 52 week high of $8.96. The stock’s 50-day moving average is $8.02 and its 200-day moving average is $8.03. The company has a market cap of $125.5 million and a price-to-earnings ratio of 56.83.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.01 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.02 by $0.01. Analysts expect that LeMaitre Vascular will post $0.23 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, June 5th. Investors of record on Thursday, May 22nd will be given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a yield of 1.74%. The ex-dividend date of this dividend is Tuesday, May 20th.

LeMaitre Vascular, Inc (NASDAQ:LMAT) is a provider of medical devices and implants for the treatment of peripheral vascular disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.